Metabolic and laboratory effects of icodextrin

Slides:



Advertisements
Similar presentations
Acid-base profile in patients on PD
Advertisements

A skeptical view of assisted home peritoneal dialysis
Volume 59, Issue 2, Pages (February 2001)
Improved patient/technique survival and peritonitis rates in patients treated with automated peritoneal dialysis when compared to continuous ambulatory.
F.H. Bender, J. Bernardini, B. Piraino  Kidney International 
Plasma sodium and hypertension
Buffer transport in peritoneal dialysis
Volume 70, Pages S138-S145 (November 2006)
Iron status and iron supplementation in peritoneal dialysis patients
Acid-base profile in patients on PD
Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis  James F. Medcalf, Kevin P.G.
Long-term follow-up of patients randomized to biocompatible or conventional peritoneal dialysis solutions show no difference in peritonitis or technique.
Use of icodextrin in high transport ultrafiltration failure
D. Teta, M. Maillard, G. Halabi, M. Burnier  Kidney International 
Impact of new dialysis solutions on peritonitis rates
Volume 64, Pages S3-S12 (December 2003)
Incremental peritoneal dialysis: Effects on the choice of dialysis modality, residual renal function and adequacy  G. Viglino, L. Neri, S. Barbieri  Kidney.
Volume 53, Issue 4, Pages (April 1998)
Glucose sparing in peritoneal dialysis: Implications and metrics
Ali K. Abu-Alfa, John Burkart, Beth Piraino, Joe Pulliam, Salim Mujais 
Volume 57, Issue 6, Pages (June 2000)
Volume 58, Issue 1, Pages (July 2000)
High volume peritoneal dialysis vs daily hemodialysis: A randomized, controlled trial in patients with acute kidney injury  D.P. Gabriel, J.T. Caramori,
James F. List, Jean M. Whaley  Kidney International 
Malnutrition and inflammation in peritoneal dialysis patients
George A. Kaysen, Burl R. Don
S.G. John, N.M. Selby, C.W. McIntyre  Kidney International 
F.H. Bender, J. Bernardini, B. Piraino  Kidney International 
Severe exfoliative skin rash with icodextrin
The epidemiology of chronic kidney disease
Edmund G. Lowrie  Kidney International 
Health-related quality of life predicts outcomes but is not affected by peritoneal clearance: The ADEMEX trial  Ramon Paniagua, Dante Amato, Edward Vonesh,
Volume 73, Pages S5-S17 (April 2008)
Pharmacokinetics of icodextrin in peritoneal dialysis patients
Volume 73, Pages S94-S101 (April 2008)
Improved patient/technique survival and peritonitis rates in patients treated with automated peritoneal dialysis when compared to continuous ambulatory.
Analysis of fluid transport pathways and their determinants in peritoneal dialysis patients with ultrafiltration failure  A. Parikova, W. Smit, D.G. Struijk,
Günter Weiss, Florian Kronenberg  Kidney International 
Volume 69, Issue 12, Pages (June 2006)
Volume 69, Issue 3, Pages (February 2006)
Tilman B. Drüeke, Ziad A. Massy  Kidney International 
Microbiology and outcomes of peritonitis in North America
Volume 74, Issue 8, Pages (October 2008)
Nephrology in Latin America, with special emphasis on Brazil
Nephrology Crossword: Peritoneal Dialysis
Future of icodextrin as an osmotic agent in peritoneal dialysis
AGEs in foods: Do they play a role in uremia?
Profiling of peritoneal ultrafiltration
Rajnish Mehrotra, Joel D. Kopple, Marsha Wolfson  Kidney International 
Volume 73, Pages S72-S75 (April 2008)
A skeptical view of assisted home peritoneal dialysis
Volume 60, Issue 2, Pages (August 2001)
Quality of life in peritoneal dialysis patients: Decline over time and association with clinical outcomes  Sr. Anne B. Bakewell, Rob M. Higgins, Mair.
Peritoneal dialysis in Mexico
Peter G. Blake, Arsh K. Jain, Sechelle Yohanna  Kidney International 
Volume 70, Pages S84-S90 (November 2006)
Biocompatibility of icodextrin
Adequacy of automated peritoneal dialysis with and without manual daytime exchange: A randomized controlled trial  D. Demetriou, A. Habicht, M. Schillinger,
Charles A. Herzog  Kidney International 
Quantification of free water transport in peritoneal dialysis
Bradley A. Warady, Mwaffek Bashir, Lynn A. Donaldson 
Review of clinical trial experience with icodextrin
Volume 59, Issue 2, Pages (February 2001)
Volume 65, Issue 1, Pages (January 2004)
The International Pediatric Peritonitis Registry: Starting to walk
Volume 59, Issue 1, Pages (January 2001)
Volume 58, Issue 5, Pages (November 2000)
Volume 58, Issue 4, Pages (October 2000)
E.F. Vonesh, J.J. Snyder, R.N. Foley, A.J. Collins 
Clinical Practice Guidelines for Peritoneal Dialysis Adequacy
Presentation transcript:

Metabolic and laboratory effects of icodextrin Ram Gokal, James Moberly, Bengt Lindholm, Salim Mujais  Kidney International  Volume 62, Pages S62-S71 (October 2002) DOI: 10.1046/j.1523-1755.62.s81.9.x Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 1 Absorption of glucose during a long dwell (8 h) is dependent on the peritoneal transport profile determined by a peritoneal equilibration test. The expected amounts of glucose absorbed at various tonicities of dialysis solution dextrose derived from validated computer modeling (PD Adequest, Baxter Healthcare Corporation, Deerfield, IL, USA [59, 60]) are shown. Symbols are: () 1.50%; (□) 2.50%; (▪) 4.25%. Kidney International 2002 62, S62-S71DOI: (10.1046/j.1523-1755.62.s81.9.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 2 Hyperglycemic and hyperinsulinemic response to oral glucose (▪) and intraperitoneal 4.25% dextrose dialysis solution (□)19. Kidney International 2002 62, S62-S71DOI: (10.1046/j.1523-1755.62.s81.9.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 3 Lack of effect of icodextrin on glucose or insulin levels during a long dwell. Kidney International 2002 62, S62-S71DOI: (10.1046/j.1523-1755.62.s81.9.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 4 A small decline in plasma sodium is observed during long-term administration of icodextrin. Data represent pooled results from several controlled trials in which the control was 2.5% dextrose (Data on file, Baxter Healthcare Corporation). Symbols are: (▪) icodextrin; (○) 2.5% dextrose; *P < 0.001 vs. 2.5% dextrose. Kidney International 2002 62, S62-S71DOI: (10.1046/j.1523-1755.62.s81.9.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 5 The acute decline in plasma sodium during a first single dwell with icodextrin parallels the increase in plasma icodextrin levels. Symbols are: (○) sodium; (▪) icodextrin. Kidney International 2002 62, S62-S71DOI: (10.1046/j.1523-1755.62.s81.9.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 6 Changes in alkaline phosphatase during long-term administration of icodextrin. Symbols are: (▪) icodextrin; (○) 2.5% dextrose. Kidney International 2002 62, S62-S71DOI: (10.1046/j.1523-1755.62.s81.9.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 7 Changes in alkaline phosphatase isoenzymes during icodextrin administration. Symbols are: () liver; (▪) bone; (□) intestinal. Kidney International 2002 62, S62-S71DOI: (10.1046/j.1523-1755.62.s81.9.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 8 Changes in plasma amylase during icodextrin administration. Symbols are: (▪) icodextrin; (○) 2.5% dextrose. Kidney International 2002 62, S62-S71DOI: (10.1046/j.1523-1755.62.s81.9.x) Copyright © 2002 International Society of Nephrology Terms and Conditions